WO1999051250A1 - Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago) - Google Patents

Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago) Download PDF

Info

Publication number
WO1999051250A1
WO1999051250A1 PCT/EP1999/002152 EP9902152W WO9951250A1 WO 1999051250 A1 WO1999051250 A1 WO 1999051250A1 EP 9902152 W EP9902152 W EP 9902152W WO 9951250 A1 WO9951250 A1 WO 9951250A1
Authority
WO
WIPO (PCT)
Prior art keywords
echinacea
extracts
treatment
cells
thrombocytopenia
Prior art date
Application number
PCT/EP1999/002152
Other languages
German (de)
English (en)
Inventor
Michel O. Ruepp
Original Assignee
Ruepp Michel O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruepp Michel O filed Critical Ruepp Michel O
Priority to AU36021/99A priority Critical patent/AU3602199A/en
Priority to EP99917908A priority patent/EP1067947A1/fr
Publication of WO1999051250A1 publication Critical patent/WO1999051250A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the use of Echinacea pallida and Echinacea angustifolia extracts, dandelion (Taraxacum) extracts, ribwort (Plantago) extracts, optionally in combination with artichoke (Cynara) extracts and / or nettle (Urtica) ) Extracts, in particular dry extracts, also in combination with other phytopharmaceuticals and / or chemically defined medicaments for the production of medicaments and for use in the context of high-dose phytopharmaceutical therapy.
  • E. pallida and E. angustifolia are very closely related.
  • Our own in-vivo studies show that the orally administered extract of E. angustifolia and E. pallida is bioequivalent.
  • the method of application made success in the treatment of viral and bacterial diseases possible.
  • Echinacea species as a kind of "omnia sanans" (panacea), for example in saddle wounds. They also target them against bacterial infections such as: - sore throat, diphtheria, meningitis, cholera, smallpox, syphilis, and typhoid
  • Echinacea tinctures were very common in the United States. Publications report healing successes in diphtheria, syphilis, typhoid, cerebrospinal meningitis, chronic laryngitis and herpes (Webster, H.T. 1898).
  • the name "taraxacum” was adopted in the Middle Ages from the writings of the Arab doctors Ibn Sina (Avicenna) and Serapion to avoid the name "Dens leonis' (dandelion), which has been known since the 13th century and recalls the toothed form of the Leaves.
  • Herbal book authors include the indications fever, cough, Gastrointestinal complaints, diarrhea, spitting blood and eye infections, taraxacum was also used as a diuretic and in wound care.
  • dandelion extract has a stimulating effect on bile and kidney function, is therefore often part of blood purification teas and is consumed as a salad from freshly collected herbs.
  • the plant contains sesquiterpene bitter substances (taraxin), triterpenes and taraxasterin, taraxasterol, taraxol, pectins, choline and inulin, especially in the roots, especially in the roots and leaves used officially.
  • the diuretic activity of a Taraxacum mother tincture in white mice is known from various sources. Dandelion crude extracts were also examined for diuretic activity in mice, with a statistically significant natri and caliuretic activity in mice.
  • Herba Taraxaci's fluid extract can result in more than 30% weight loss compared to baseline in mice and rats after the end of treatment.
  • Aqueous extracts have no choleretic effect. Furthermore, it is known that Taraxacum officinale in a study on SCALD mice with suppressed immune status showed stimulating effects on cell-mediated immunity, the humoral and cellular immune system.
  • Planta which means both “plant / seedling” and “sole of the foot” (especially the leaves of the plantain / Plantago major have a certain similarity to the sole of the foot).
  • “Lanceolata” goes back to Latin “lancea”: “lance”, “spear” and refers to the narrow, pointed shape of the leaves of the plantain.
  • Plantain refers to the location of the plant; it can be traced back to Gothic and Old High German ('hh [h] i': king) and originally means something like "master of the way".
  • the plant also plays an important role in medieval literature. In general, their hemostyptic, blood cleansing, antispasmodic and expectorant (and thus expectoration-promoting), antifebrile and wound healing effects are emphasized. - 5 -
  • the object of the present invention is to provide new drugs and thus new therapeutic options by using Echinacea pallida (EP) - and Echinacea angustifolia (EA) -, dandelions (Taraxacum, TA) - and ribwort (Plantago, PL) extracts.
  • EP Echinacea pallida
  • EA Echinacea angustifolia
  • dandelions Taraxacum, TA
  • ribwort Planttago, PL
  • a first embodiment of the present invention consists in the use of EP, EA, TA and PL extracts, in particular dry extracts for lowering the serum values of cholesterol, triglycerides, blood glucose, creatinine and / or bilirubin, GOT, GPT, GGT cellular immune stimulation, for the therapy of leukocytopenia, granulocytopenia, lymphocytopenia, thrombocytopenia, erythrocytopenia and for the treatment of radiation, infection and chemical-related damage to organs and tissues of the intestine, in particular the O-MALT system of the small intestine. of the lungs, bronchi and nasopharynx, bone marrow, thymus, spleen, lymph nodes, liver, pancreas and kidneys.
  • EP, EA, TA and PL experimentally increase liver parenchymal protein biosynthesis after oral administration.
  • the pronounced activation of the liver metabolism also explains the clear clinical influence on the increased activities of liver-specific enzymes such as GOT, GPT, Gamma-GT, GLDH and LDH as a result of infectious hepatitis.
  • EP, EA, TA and PL thus show curative effects on infectious liver cell damage.
  • the stimulation of the normal activity of the lymphopoietic cell system especially that of the T-lymphocytes (hyperplasia), documents the central event of the paramunization by Echinacea aar.
  • This activated state will also influenced by the stimulation of liver parenchymal protein biosynthesis.
  • the type and intensity of the initial immune response depends largely on the functional state of the T-
  • EP, EA, TA and PL not only leads to a non-pathogen and non-antigen-specific protection (paramunity) against various infectious agents, but also increases the already developed - often reduced
  • EP, EA, TA and PL also stimulate granulocyte and macrophage phagocytosis, the antibacterial effect can also be justified. Based on experimental and clinical reports and examinations, EP, EA, TA and PL are clinically effective in bacterial and viral-induced diseases, such as: angina, bronchitis, laryngitis, otitis, sinusitis, lymphadenitis, eyelid margin infection,
  • EP, EA, TA and PL show no signs of undesirable effects, neither in the experimental studies carried out nor in clinical studies.
  • the multiantigenic effect of the extractive substances (synergy effect of the individual ingredients and active ingredients, multiantigenicity) ultimately induces non-specific immune stimulation (paramunization, immunomodulation, immunotherapy).
  • EP, EA, TA and PL extracts act as paramunity inducers antiviral, antibacterial and antitumoral (anticarcinogenic).
  • Medication with immunoregulatory substances are substances that nonspecifically intervene in immune processes and intervene. (Mayer, A. et al. 1979).
  • immunostimulants seem to have in common that they are surface-active and activate the lymphocytes and macrophages responsible for the formation of immunity, such as gram-positive bacteria or their components.
  • Listeria monocytogenes preferentially stimulates the B lymphocytes, Corynbacterium parvum the macrophages and BCG the T lymphocytes (Hahn 1978).
  • Paraspecific inhibitory effects on non-pathogen and non-antigen-related infections have also become known for numerous vaccinations, for example smallpox vaccinations for the therapy of herpes simplex or BCG vaccination as additional therapy for tumors.
  • Paraspecific effects are induced by: a: increase in phagocytosis b: activation of the lymphopoietic cell system c: formation of interferon d: stimulation of humoral factors.
  • the local administration of the vaccine is apparently better for parasites than parenteral vaccination.
  • stimulation of the lymphopoietic cell system - especially that of the T lymphocytes - not only leads to a faster and stronger reaction with specific antigens, but also to an increase in the function of already antigen-specified T and B lymphocytes, whereby the stimulation of the T-cell-like repressor cells has a favorable regulatory effect (Mayer, A. et al., 1979).
  • the responsiveness of the phagocytic and lymphopoietic cell system does not appear to be due to a lymphopoetic multiplication of the phagocytes or lymphocytes to be based, but to be the result of an increase in metabolism (Mayer, A., et al., 1979).
  • a paramunity can be acquired naturally and artificially, both systemically and locally via the mucous membranes of the respiratory, digestion and urogenital tract.
  • the locally acquired paramunity is of particular importance (Mayer, A. et al., 1979).
  • EP, EA, TA and PL Treatment with EP, EA, TA and PL leads to an increase in the number of mobile B-lymphocytes in the follicles as well as the T-lymphocytes in the PALS, as well as to an increase in the lymphocytes in the peripheral blood.
  • EP, EA, TA and PL clearly shows that the stimulation is obviously not based solely on a numerical increase in lymphocytes, but that it is the result of an increase in metabolism (Mayer, A. et al., 1979) increase the metabolic activity of the hepatocytes, which among other things leads to increased protein biosynthesis.
  • Macrophages for example interferon, interleukin 1 and tumor necrosis factor c: increase in properdin level d: antiviral effect against influenza virus, genital herpes virus and
  • Viscular stomatitis virus Viscular stomatitis virus.
  • EP, EA, TA and PL are primarily capable of the function and performance of granulocytes and macrophages - important immune-competent cells of the non-specific
  • a paramunity - the developing "immediate defense of an organism" can be acquired in a natural as well as an artificial way (Mayer, A. et al., - 1 1 -
  • the protective effect of a naturally acquired paramunity against various infections also includes a protective function against carcinogenesis.
  • neoplasts can be directly inhibited "by artificial means” by stimulating macrophages or T-killer cells (Wagner, H., 1,983).
  • Paracortical hyperplasia is induced as early as 7 days after the injection of tumor cells. Reactions of the germ centers were observed in later stages of tumor growth, sometimes only after metastasis had broken out. On the 21st day, a clearly recognizable sinus histiocytosis developed, which decreased slightly as a result of advanced lymphogenic metastasis. Under the influence of an experimentally induced tumor, the histomorphology of the lymph node changes significantly chronologically even before - 12 -
  • the T cell areas and the undamaged pulp (paracortical zone and follicular cortex zone) of group II are significantly larger than those in group I (p ⁇ 0.05) . It was striking that the size of the B cell areas had no correlation with the carcinogenesis of the colon carcinoma.
  • the results of the histological changes in the T cell areas in the lymph nodes during the phase up to metastasis allow a description of the status of the immune status and prognoses.
  • the progression as well as the spontaneous regression of the tumor is not only influenced by the tumor but also by the type and intensity of the initial immune response (paramunity).
  • HSV herpes simplex virus
  • the antibodies formed by an initial infection with HSV 1 and 2 cannot provide complete protection against immunity in subsequent reinfections with the same or with the other virus type. However, the antibodies can reduce the severity of subsequent infections and shorten their duration.
  • Macrophages play a significant part in the defense against HSV infections. They are not only directly involved in the response of the T and B lymphocytes, but also. also crucial in controlling viral development. This includes phagocytosis of virions, the inhibition of viral replication by destroying virus-infected cells, and the induction of interferon production. This slows down or prevents the virus from spreading to non-infected cells.
  • the cellular immune response to a herpes infection is crucial for the recovery process
  • T-lymphocytes primarily exercise control functions in the herpes infection. Therefore, patients with suppressed cellular immunity with reduced or dysfunctional T cells are particularly susceptible to severe forms (Graham, Snell 1983). An example of this is infection with HIV (Human - 14 -
  • immunodeficiency virus whereby the immunological primary deficit is characterized by the virus-induced damage to the helper T / inducer T lymphocytes (Clumek et al. 1984).
  • the progression of HSV infection is decisively influenced by the type and intensity of the initial immune response (paramunity) by the lymphatic system.
  • EA, TA and PL are obviously critical in controlling viral development by activating the macrophages and the - 15 -
  • lymphopoietic cell system especially that of T-lymphocytes.
  • EP, EA, TA and PL thus also stimulate virus-related, suppressed, cellular immunity.
  • AAR antigen-antibody reaction
  • Immunity to bacteria is dominated not by specific and non-specific defense factors, but by the performance of antigen-unspecific phagocytic cells. These destroy the invaded microorganisms or prevent them from spreading.
  • the clear curative effect of EP, EA, TA and PL on lid margin infections and sinusitis is obviously shaped by stimulation of the granulocyte and macrophage phagocytosis.
  • Echinacea pallida Echinacea pallida
  • EA Echinacea angustifolia
  • Taraxacum TA dandelion
  • Plant PL ribwort
  • the object of the present invention is in particular to provide new use forms for Echinacea pallida and Echinacea angustifolia.
  • the above object is achieved according to the invention by the use of Echinacea pallida and Echinacea angustifolia extracts for cellular immune stimulation for induction of an increased non-specific immune defense (paramunization), for adjuvant therapy for inflammation, for improving the oxygen supply to the cell metabolism, for improving the flow properties of the Blood, to improve renal function and to protect the liver and heal.
  • the echinacea extract was examined in the context of an in vivo study in rats.
  • Echinacea pallida Echinacea angustifolia
  • EA Echinacea pallida
  • GALT well associated lymphoid tissue
  • micromorphological substrate of this orally induced stimulation speaks - 18 -
  • Echinacea pallida Echinacea angustifolia
  • lymph node histologically one can recognize a re-colonization of the reticular tissue with cells of the lymphatic group.
  • lymphatic group In the paracortical zone there are densely packed, intact lymphatic cells, in the cortical zone there are loose, intact lymphocytes with a clear tendency towards subcapsular follicle formation.
  • lymphoreticular tissue In the case of the lymph node, histologically one can recognize a re-colonization of the reticular tissue with cells of the lymphatic group. In the paracortical zone there are densely packed, intact lymphatic cells, in the cortical zone there are loose, intact lymphocytes with a clear tendency towards subcapsular follicle formation. With the restoration of the characteristic microstructure of the lymphoreticular tissue in the lymph node, its function obviously starts again.
  • lymph node has gained practical importance: If stimulation of the T cells (paracortical zone) is observed in the drainage area of carcinomas (breast carcinoma, portiocarcinoma), the patient has a better prognosis than when the B cell is activated. Region or no lymph node response.
  • Another object of the present invention is to provide new application forms for dandelion extracts.
  • lion tooth extracts for cellular immune stimulation, for adjuvant therapy for inflammation, for improving the oxygen supply to the cell metabolism, for improving the flow properties of the blood, for improving renal function and for liver protection and healing function .
  • the dandelion extract was examined which, in comparison with a control group, induced:
  • Hemoglobin content the hematocrit value, the content values of potassium
  • Triglyce den creatinine, GLDH, GOT and GPT.
  • the cell numbers of the segmental nuclei increased in comparison with the control group.
  • Granulocytes, T and B lymphocytes, helper and suppressor cells as well as NK cells clearly. - 20 -
  • the following are considered to be therapeutically desirable: the increase in the number of granulocytes, leukocytes and lymphocytes as well as the corresponding subsets as adjuvant for an anti-inflammatory effect (paramunization); - Lowering cholesterol and trigiyceride levels to improve
  • Fluidity of the blood the marked reduction in creatinine and urea levels with the simultaneous increase in potassium as an improvement in renal function; the marked reduction in bilirubin and the enzymes GLDH, GOT and GPT as markers for a clear hepatoprotective and curative
  • mice Male Wistar rats were divided into two groups and treated with dandelion extracts once a day for 7 days intragastric. Subsequently, blood was taken retroorbitally from the animals and then analyzed in vitro fully automatically and hematologically quantitative: leukocytes, erythrocytes, hemoglobin, hematocrit, mean cell volume (MCV), mean corpuscular hemoglobin (MCH), mean hemoglobin concentration of the erythrocytes MCH.
  • MCV mean cell volume
  • MCH mean corpuscular hemoglobin
  • leucocyte differentiation was carried out by flow cytometry after specific monoclonal incubation using fluorescence-activated cell sorting.
  • the clinical parameters such as bilirubin, creatinine, urea, GLDH, GOT, GPT, AP, glucose, cholesterol, triglycerides, calcium, sodium, potassium, chloride and total protein were recorded selectively, photometrically or with the aid of ion-selective electrodes.
  • TDS taraxacum extract
  • dandelion extracts showed no undesirable effects at the tested dosage of 100 mg / kg body weight and the parameters used for the evaluation.
  • the fresh plant in particular pressed juice, in dried form, in particular powder or infusion, is suitable as an application form, in particular as a tincture
  • methanol is particularly preferably used as an extracting agent for the plant.
  • Another object of the present invention is to provide new uses for ribwort extracts.
  • ribwort extracts for cellular immune stimulation, for induction of an increased non-specific immune defense (paramunization) and an increased function of the mucus-producing goblet cells in the epithelium of the small intestine and the bronchi in the lungs, furthermore the PL extracts, used for adjuvant therapy for inflammation, to improve the flow properties of the blood, to improve renal function and to protect the liver and healing organs.
  • the plantain extract was examined in the context of the in vivo study on rats.
  • lympho-reticular tissue Under the influence of the test substance PL, micromorphologically demonstrable hyperplasia of the lympho-reticular tissue occurs in the secondary lymphatic organs mentioned (lymph nodes, subepithelial accumulations of lymphatic tissue, spleen and thymus), the T-lymphocyte areas appearing more stimulated than the B-lymphocyte areas .
  • the hyperplasia of the paracortical zones impress in the lymph nodes and the Peyer's plaques, and the hyperplasia of the marginal zones in the spleen.
  • the microarchitecture of the thymus is unchanged, but the density of lymphatic cells in the cortical zones is increased.
  • oral treatment with PL primarily leads to an increased non-specific immune defense (Paramuntician: Mayer et al. 1979), as it were ascending from the application site via Peyer's plaques and the subepithelial accumulations of lymphoid tissue into the lymph nodes of the abdominal cavity organs and ultimately the spleen. - 24 -
  • T-lymphocytes as well as the other lymphocyte subsets could be measured in the present in vivo study after specific monoclonal incubation by means of fluorescence-activated cell sorting in the blood:
  • the signs of an increased function of the goblet cells in the small intestine as well as the indicated increase in the proliferation of the glandular epithelium in all animals of group II (PL) can also be attributed to a local effect of the test substance.
  • Group II liver substrate can be interpreted in terms of improved liver function. It would be conceivable to have this effect of Plantago in mind - 25 -
  • liver protection therapeutically.
  • Animals and ⁇ ierharm Male Wistar rats were g with an average body weight of 321 under conventional conditions at a room temperature of 21 +/- 1 ° C, a relative humidity of about 60% and a 12 hour day held / night rhythm. Before the start of the experiment, they were subject to an acclimatization period of 12 days.
  • the diet was carried out with the pelleted standard diet Altromin C1000, Misch. No. 100 (Altrogge company, location); the animals received tap water ad libidum as drinking water.
  • Drageekern granules with dry extract from dried roots of Echinacea pallida EP (Ch. No. 1134), extracting agent methanol 30 vol.%, Ch. No. 113934, herb of Taraxacum officinale (TD), extracting agent ethanol (60% v / v).
  • EP was administered intragastric to the non-sedated animals once a day for 7 days using a rigid button probe.
  • the suspension was freshly prepared immediately before application and applied homogeneously.
  • the aim of the investigations was to use a defined in-vivo model to simultaneously acquire specific markers that indicate the therapeutic effect as a synergistic effect of differently influenced physiological control circuits at an early stage.
  • Ery Erythrocytes, (Ery), leukocytes (Leu), platelets (Plt), hemoglobin
  • MCV Mean cell volume
  • MCH mean corpuscular hemoglobin
  • MCHC mean hemoglobin concentration of erythrocytes
  • RW erythrocyte distribution width
  • Leukocyte differentiation granulocytes, monocytes, lymphocytes, B and
  • T cells helper and suppressor cells
  • Creatinine, urea, total protein Creatinine, urea, total protein.
  • the main unit of this device essentially consists of a hydraulic (HS) and an electronic system (ES).
  • the HS is used to aspirate, pipette, dilute, mix and lyse.
  • the ES analyzes and converts the signals from the HS and transmits the results to the printer.
  • the ES also monitors the test processes, the test station and carries out quality control.
  • the hematocrit value indicates the percentage volume of the erythrocytes in the blood.
  • Hemoglobin the chromoprotein contained in the erythrocytes, is an important criterion for the diagnosis of anemia in addition to the number of erythrocytes and the hematocrit value.
  • the classification is based on the erythrocyte indices. - 28 -
  • the red cell distribution width (RDW) is a measure of anisocytosis.
  • the parameters such as enzymes, glucose, lipids, electrolytes, creatinine, urea and protein are recorded with the aid of the Cobas Mira analyzer in a method-oriented, photometric or ion-selective manner.
  • the general well-being of the animals was checked during acclimatization before the start of the experiment and throughout the entire duration of the experiment. In addition, the body weight was determined daily.
  • test substance EP was indirectly determined by its stimulating effect on the number of leukocytes (WBS), erythrocytes (RBC) and thrombocytes (Plt).
  • WBS leukocytes
  • RBC erythrocytes
  • Plt thrombocytes
  • the samples of groups I and II were analyzed in vitro by flow cytometry, the measurement of the cell size and the granularity making possible the discrimination of leukocytes, monocytes and granulocytes on the basis of the registration of corresponding scattering intensity.
  • the strength of the immunopotentials of the test substances in group II (EP) with regard to their biological action was determined with the aspect of changing the cell number of the lymphocyte population.
  • T and B lymphocytes, helper and suppressor cells and NK cells were differentiated and quantified by flow cytometry using immunofluorescence.
  • the cell counts of segmented granulocytes, T and B lymphocytes, helper and suppressor cells and NK cells were increased compared to the control group.
  • NK cells 25.86% - granulocytes 13.14%
  • Bilirubin creatinine, urea, glutamate dehydrogenase (GLDH), glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), alkaline phosphatase (AP), glucose, cholesterol, triglycerides, calcium, sodium, potassium, chloride and total protein.
  • GLDH glutamate dehydrogenase
  • GAT glutamate oxaloacetate transaminase
  • GTT glutamate pyruvate transaminase
  • AP alkaline phosphatase
  • glucose glucose
  • cholesterol triglycerides
  • calcium sodium, potassium, chloride and total protein.
  • Echinacea pallida EP
  • EA Echinacea angustifolia
  • the histological examinations were carried out after formalin fixation of the organ samples on paraffin sections (Medim Plast) with hematoxylin-eosin staining (H.E.) and additionally on the liver on frozen sections with fat staining (il-Rot-O).
  • flu infection refers to a viral infection of the respiratory tract which manifests itself in inflammation of the mucous membranes, which can be triggered by various viruses (e.g. influenza viruses, rhinoviruses, parainfluenza viruses, ECHO viruses, etc.).
  • the "flu infection” is the most common human disease; the transmission takes place by droplet infection. The disease mainly occurs in the cold season, since hypothermia leads to reduced blood flow to the mucous membranes and the body's defenses are weakened. This explains the colloquial term “cold”.
  • the "flu infection” manifests itself in the following clinical pictures: tracheobronchitis (trachea and central airways), rhinitis, tonsillitis, pharyngitis - 32 -
  • Rhinitis is a catarrhal or serous mucus inflammation, like a simple runny nose. Conjunctivitis also focuses on edema of the connective tissue with hyperemia, itching and lacrimation. In the area of the larynx, tracheal and bronchial mucosa there is a high degree of hyperemia with small bleeding as a result of stronger toxic vascular lesions, which give these mucous membranes a "flaming" flush.
  • Echinacea pallida extract coated tablets were administered in the following standard dose: 3 x 3 coated tablets / day before meals.
  • Herpes infections are triggered by the herpes simplex virus (HSV), which occurs in the two main types HSV I and HSV II.
  • HSV herpes simplex virus
  • the transmission takes place mostly in infancy or infancy through droplet infection or direct skin contact.
  • the primary infection is clinically normal and can only be detected by the presence of homologous antibodies.
  • antibodies there is no complete elimination of the herpes simplex virus, which remains in the organism and leads to a non-productive latent infection phase.
  • a reactivation of the latent herpes simplex virus then leads to secondary and subsequent infections, i.e. to recurrent herpes.
  • Various exogenous factors can be mentioned as the cause of the occurrence of recurrences: e.g. Infectious diseases, strong sun exposure, menstruation, mechanical trauma, food intolerance, psychological stress.
  • the characteristic feature of an infection with herpes viruses is that after the initial infection the viruses retreat along the nerve pathways that supply the entry area to the ganglia. They remain in this "hiding place” for a lifetime, in many cases without causing any symptoms of the disease. Only about ten percent of those infected have an initial infection - 36 -
  • the herpes viruses "sleeping" in the nerve nodes can be reactivated. Around eight to ten million Germans in Germany have a recurrence at more or less regular intervals - some even suffer from cold sores every month. The herpes viruses then migrate back to the area of skin into which they entered during the initial infections and cause the disease to break out again. Clinical observations indicate that a defect or change in the immune system is the possible cause of the relapse. For example, reactivity disorders of the immune cells were found in the lymphocyte transformation test, the macrophage inhibition inhibition test and the lymphocyte toxicity test. The reduced interferon production during HSV infection also indicates a reduced cellular immune competence.
  • herpes simplex diseases can be divided into two groups, which are characterized by their location.
  • Herpes labiales diseases occur primarily on the lips, but also on the oral mucosa and the skin on the head and upper body, they are induced by HSV I.
  • HSV II predominantly leads to genital herpes diseases (lower half of the body, especially the genital and gluteal regions).
  • prodronic signs of a disease itching, burning and a feeling of tension may appear in the affected area.
  • erythema usually grouped, weeping vesicles develop.
  • swelling and pain are very common.
  • the lesions usually heal within about 10 days with scab formation.
  • the treatment period until the herpes lesions healed averaged 5 days. In comparison to the usual average disease duration of 10 days, this must be seen as a clear treatment success of Echinacea therapy.
  • Echinacea angustifolia / pallida extract therapy was rated "good or very good" by 16 patients. There were no side effects. - 38 -
  • echinacea is administered simultaneously with radiation and chemotherapy in a dose of 3 x 3 coated tablets / day, the radiation or chemotherapy-related immunosuppressive potential can obviously be significantly reduced.
  • Echinacea is applied following a radiation or therapeutic measure, it can be established that Echinacea with an application of 3 x 2 to 3 x 3 coated tablets over a period of 1 to 2 months reduces the therapy-related number of lymphocytes by approx. 30 to 50% and that of the granulocytes can increase by approx. 20 to 30%. - 39 -
  • Male Wistar rats with an average body weight of 321 g were kept under conventional conditions at room temperature (21 +/- 1 ° C), a relative humidity of about 60% and a 12 hour day / night rhythm. Before the start of the experiment, they were subject to an acclimatization period of 12 days.
  • the diet was based on a standard pelleted Altromin C 1000 Misch diet. No. 100 (company Altrogge Lü).
  • the animals received tap water ad libidum as drinking water.
  • TDS was administered intragastric to the non-sedated animals once a day for 7 days using a rigid button probe.
  • the suspension was freshly prepared immediately before application and applied homogeneously.
  • TDS leukocytes
  • RBC erythrocytes
  • PIt thrombocytes
  • the index MCV represented the quotient of hematocrit and erythrocyte number
  • the index MCH the quotient of hemoglobin and erythrocyte number
  • the index MCHC the quotient of hemoglobin and hematocrit value
  • the samples of groups I and II were analyzed in vitro by flow cytometry, the measurement of the cell size and the granularity making possible the discrimination of leukocytes, monocytes and granulocytes on the basis of the registration of corresponding scattering intensity.
  • TDS T and B lymphocytes, helper and suppressor cells and NK cells were differentiated and quantified by flow cytometry using immunofluorescence.
  • the cell counts of segmented granulocytes, T and B lymphocytes, helper and suppressor cells and NK cells were increased compared to the control group.
  • NK cells by 40.3% granulocytes by 53.0%
  • Bilirubin ⁇ creatinine, H_amsi ⁇ fiJ3lukose, _Lipid_e, electrolytes jndJ ⁇ i The following metabolic parameters were combined and analyzed in a method-specific manner:
  • Bilirubin creatinine, urea ,.
  • Glutamate dehydrogenase GLDH
  • GT glutamate oxaloacetate transaminase
  • GT glutamate pyruvate transaminase
  • AP alkaline phosphatase
  • Male Wistar rats with an average body weight of 324 g were kept under conventional conditions at a room temperature of 21 +/- 1 ° C, a relative humidity of about 60% and a 12 hour day / night rhythm. Before the start of the experiment, they were subject to an acclimatization period of 12 days.
  • the diet was carried out with the pelleted standard diet Altromin C1000, Misch. No. 100 (Altrogge company, location); the animals received tap water ad libidum as drinking water.
  • Drageekerngranulat with standardized commercial dry extract from ribwort herb (3-6: 1); Extracting agent: purified water DAB 10, Ch.-Nr. 019144; Parent drug: Ribwort herb (Plantaginis lanceolatae herba) DAB 10; 1 coated tablet Plantago N with 445 mg contains 80 mg native plantain herb extract (3-6: 1; PL).
  • PL was administered intragastric to the non-sedated animals once a day for 7 days using the rigid button probe.
  • the suspension was freshly prepared immediately before application and applied homogeneously.
  • WBS leukocytes
  • RBC erythrocytes
  • PIt platelets
  • test substance PL a clear increase in the number of leukocytes by 41.8% and an increase in the number of erythrocytes by 5.5%
  • the index MCV represents the quotient from hematocrit and erythrocyte number
  • the index MCH the quotient from hemoglobin and erythrocyte number
  • the index MCHC the quotient from hemoglobin and hematocrit value
  • the strength of the immunopotentials of the test substances in group II (PL) with regard to their biological action was determined with the aspect of changing the cell number of the lymphocyte population.
  • T and B lymphocytes, helper and suppressor cells and NK cells were differentiated and quantified by flow cytometry using immunofluorescence.
  • test substance PL of: - leukocytes by 41.8%
  • Bilirubin creatinine, urea, glutamate dehydrogenase (GLDH), glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), alkaline phosphatase (AP), glucose, cholesterol, triglycerides, calcium, sodium, potassium, chloride and total protein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne principalement l'utilisation d'extraits d'Echinacea pallida (EP), d'Echinacea angustifolia (EA), de dents de lion (Taraxacum, TA) et de plantain (plantago, PL), en particulier des extraits secs provenant de plantes fraîches ou séchées, pour la fabrication de médicaments pour le traitement ou la prévention (protection) contre les rayonnements (radioprévention, radioprotection), altérations des organes et des tissus dues à des infections (prophylaxie infectieuse) et à des agents chimiques (chimioprévention, chimioprotection, en particulier du système O-MALT de l'intestin grêle (maladies inflammatoires, entérite régionale, maladie de Crohn) du poumon (inflammation, affection), des bronches et de la région rhinopharyngée (bronchite rhynopharyngée, rhinite, pharyngite, sinusite), de la moelle osseuse (aplasie de la moelle osseuse), du thymus (dysfonctionnement, aplasie ou hypoplasie par suite d'endommagement dû à des médicaments ou à des rayonnements), du foie (atrophie, nécrose), hépatite A, B et C du pancréas, insuffisance de la fonction exocrine, sécrétoire des protéases, estérases, carbohydrases et nucléases, ainsi que des troubles fonctionnels endocrines du métabolisme des hydrates de carbone (îlots de Langerhans) et des reins (insuffisance rénale) et des états immunosuppresseurs en général, pour l'immunostimulation cellulaire, pour le traitement de leucocytopénie, granulocytopénie, lymphocytopénie, thrombocytopénie, érythrocytopénie (notamment, anémie infectieuse ou tumorale) et pour des états déficitaires en immunoglobuline, également à la suite de SIDA, tumeurs et affections à système immunosuppresseur.
PCT/EP1999/002152 1998-04-02 1999-03-26 Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago) WO1999051250A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU36021/99A AU3602199A (en) 1998-04-02 1999-03-26 Use of extracts of echinacea pallida and echinacea angustifolia, dandelion (taraxacum) and plantain (plantago)
EP99917908A EP1067947A1 (fr) 1998-04-02 1999-03-26 Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814725.2 1998-04-02
DE19814725A DE19814725A1 (de) 1998-04-02 1998-04-02 Verwendung von Echinacea-pallida und Echinacea angustifolia-Extrakten; Löwenzahn-/Taraxacum)-Extrakten; Spitzwegerich-(Plantago)-Extrakten

Publications (1)

Publication Number Publication Date
WO1999051250A1 true WO1999051250A1 (fr) 1999-10-14

Family

ID=7863315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/002152 WO1999051250A1 (fr) 1998-04-02 1999-03-26 Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago)

Country Status (4)

Country Link
EP (1) EP1067947A1 (fr)
AU (1) AU3602199A (fr)
DE (1) DE19814725A1 (fr)
WO (1) WO1999051250A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132969A1 (fr) * 2009-05-21 2010-11-25 Ybios S.A. Compositions photoprotectrices comprenant des extraits de cynara scolymus et d'echinacea purpurea
CN111617146A (zh) * 2020-06-05 2020-09-04 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) 一种治疗小儿咽部炎症的中药雾化液
US11147835B1 (en) 2020-08-20 2021-10-19 Frank Kelly Reilly, III Nutritional supplement

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1602200A (zh) * 2001-11-16 2005-03-30 董事研究有限责任合伙公司 具有免疫刺激剂活性的植物提取物
EP1325681A1 (fr) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Composition pour la promotion de la croissance osseuse et la conservation de la santé osseuse
EP1325682A1 (fr) * 2001-12-11 2003-07-09 Societe Des Produits Nestle S.A. Aliment humain ou de bétail comprenant des extraits végétaux pour la conservation de la santé osseuse et la prévention ou le traitement des maladies des os
TWI269656B (en) * 2003-03-05 2007-01-01 Original Image Co Ltd Therapeutical composition for hepatitis C
DE10346950A1 (de) * 2003-10-09 2005-07-07 Heinz Kiefer Verwendung eines Arzneimittels (Tumorthera peutikum) in Kapselform zur Langzeitbehandlung bösartiger Geschwulsten (prä- und postoperativ), Zusatzbehandlung während der Strahlentherapie, zur Metastasenprophylaxe und bei Chemotherapieresistenz, dadurch gekennzeichnet, daß eine Kapsel eine Kombination von Viscialbiherba, Echinacea pallidae radix, Hypericiherba und Papain enthält

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB939735A (en) * 1960-07-19 1963-10-16 Louis Lafon A process for the preparation of a therapeutic extract of taraxacum dens leonis and pharmaceutical compositions thereof
DE3744571A1 (de) * 1987-12-30 1989-07-13 Lohmann Rudolf Lomapharm Pharmazeutische zubereitungen zur stimulierung des immunsystems und verfahren zu ihrer herstellung
DE3744570A1 (de) * 1987-12-30 1989-07-13 Lohmann Rudolf Lomapharm Pharmazeutische zubereitungen mit immunstimulierender wirkung und verfahren zu ihrer herstellung
CH676931A5 (en) * 1988-08-02 1991-03-28 Spagyros S A Herbal medicaments prodn. - contg. essential antimicrobial oils and Echinacea tinctures, for treating infections, etc.
WO1998011778A1 (fr) * 1996-05-08 1998-03-26 Meryl Squires Traitement antimicrobien du virus de l'herpes simplex et d'autres maladies infectieuses
EP0870507A1 (fr) * 1997-04-02 1998-10-14 Farmo-Nat Ltd. Extraits synergiques d'herbes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB939735A (en) * 1960-07-19 1963-10-16 Louis Lafon A process for the preparation of a therapeutic extract of taraxacum dens leonis and pharmaceutical compositions thereof
DE3744571A1 (de) * 1987-12-30 1989-07-13 Lohmann Rudolf Lomapharm Pharmazeutische zubereitungen zur stimulierung des immunsystems und verfahren zu ihrer herstellung
DE3744570A1 (de) * 1987-12-30 1989-07-13 Lohmann Rudolf Lomapharm Pharmazeutische zubereitungen mit immunstimulierender wirkung und verfahren zu ihrer herstellung
CH676931A5 (en) * 1988-08-02 1991-03-28 Spagyros S A Herbal medicaments prodn. - contg. essential antimicrobial oils and Echinacea tinctures, for treating infections, etc.
WO1998011778A1 (fr) * 1996-05-08 1998-03-26 Meryl Squires Traitement antimicrobien du virus de l'herpes simplex et d'autres maladies infectieuses
EP0870507A1 (fr) * 1997-04-02 1998-10-14 Farmo-Nat Ltd. Extraits synergiques d'herbes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132969A1 (fr) * 2009-05-21 2010-11-25 Ybios S.A. Compositions photoprotectrices comprenant des extraits de cynara scolymus et d'echinacea purpurea
CN111617146A (zh) * 2020-06-05 2020-09-04 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) 一种治疗小儿咽部炎症的中药雾化液
CN111617146B (zh) * 2020-06-05 2021-10-15 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) 一种治疗小儿咽部炎症的中药雾化液
US11147835B1 (en) 2020-08-20 2021-10-19 Frank Kelly Reilly, III Nutritional supplement

Also Published As

Publication number Publication date
DE19814725A1 (de) 1999-10-07
EP1067947A1 (fr) 2001-01-17
AU3602199A (en) 1999-10-25

Similar Documents

Publication Publication Date Title
DE60117711T2 (de) Antineoplastisches arzneimittel
EP0912189A1 (fr) Utilisation des extraits d'artichauts (cynara)
KR100671432B1 (ko) 천식의 유지치료용 약제
EP0125634B1 (fr) Utilisation d'une substance sécrétolytique pour l'obtention d'un agent contre le ronflement et pour combattre le phénomène de ronflement
WO1999051250A1 (fr) Utilisation d'extraits d'echinacea pallida et d'echinacea angustifolia; extraits de dents de lion (taraxacum); extraits de plantain (plantago)
EP0932410B1 (fr) Extraits de gui (viscum)
DE4418976A1 (de) Phytotherapeutikum und Verfahren zu seiner Herstellung
Ajibade et al. Histopathological and toxicological effects of crude saponin extract from Phyllanthus niruri, L (Syn. P. franternus. Webster) on organs in animal studies
US8158159B2 (en) Pharmaceutical formulation for treating tinea of feet and hands and preparation thereof
CH676931A5 (en) Herbal medicaments prodn. - contg. essential antimicrobial oils and Echinacea tinctures, for treating infections, etc.
CN115025112B (zh) 白芷多糖在制备防治溃疡性结肠炎的药物中的用途
EP0256353A2 (fr) Traitement pharmaceutique contre une mauvaise absorption d'aliments ou de médicaments oraux
CN109125703A (zh) 一种用于治疗阴道炎的药物组合及其制备方法
Mushtaq et al. Anti-nociceptive and anti-inflammatory activity of Trapa bispinosa, Chenopodium album and Cuscuta reflexa
WO2022077358A1 (fr) Compositions de soins et leur utilisation
EP1067948A1 (fr) Utilisation d'extraits de feuilles de busserole(arctostaphylos uva ursi), de feuilles de bouleau (betula), de prele (equisetum) et d'ortie brulante (urtica)
EP2268294A1 (fr) Extrait de propolis
DE2015877A1 (de) Arzneimittel
Kusuma et al. An experimental evaluation of the Lithotriptic Activity of Ayurvedic drug Kāśīśa Bhasma
DE102004008375B4 (de) Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege
DE2162190A1 (de) Medikament zur Behandlung von Geschwüren
Ampa et al. ANTIDIABETIC ACTIVITY AND CHEMICAL SCREENING OF THE AQUEOUS EXTRACT OF SEEDS OF STRYCHNOS CAMPTONEURA GILG & BUSSE (LOGANIACEAE)
WO2023242339A1 (fr) Composition comprenant de la pétasine et de l'isopétasine ayant un effet hépatoprotecteur
CN113876849A (zh) 一种化石中药组合物及其制作工艺
EP0711170A1 (fr) Composition pharmaceutique contenant des lymphocytes t utilisee pour le traitement d'infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999917908

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999917908

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999917908

Country of ref document: EP